The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$250 million milestone from partner Jazz Pharmaceuticals.

The FDA decision appears to have reinforced investor confidence in Zymeworks, with the stock posting a 27.41% 1 month share price return and a 96.28% 1 year total shareholder return, while the 298.71% 3 year total shareholder return points to momentum that has been sustained over a longer period.

Track how Zymeworks fits into a wider biotech toolkit by scanning a curated 20 high quality undiscovered gems, which are also leveraging partnerships and pipelines to pursue growth in complex diseases.

Zymeworks now has an FDA approved drug, a large milestone payment and a long track record of volatile returns. The next step is simple: do these strengths still justify the current share price after the latest jump?

Most Popular Narrative: 25.3% Undervalued

The most followed narrative on Zymeworks compares a fair value of $39.23 to the last close at $29.31, which frames the recent rally as only part of the story.

The increasing global incidence of cancer and chronic diseases, driven by an aging population, is expanding the potential market for Zymeworks' oncology and biologic therapies, positioning its diversified pipeline (including ADCs like ZW171, ZW191, ZW251, and zanidatamab) for long-term addressable revenue growth as regulatory approvals, new indications, and commercial launches progress.

Want to see what sits behind that growth blueprint for Zymeworks? The central storyline links rapid top line expansion, shifting margins, and a rich future earnings multiple into one valuation view.

Result: Fair Value of $39.23 (UNDERVALUED)

However, the Zymeworks narrative still hinges on irregular milestone payments and early stage pipeline assets, where clinical or regulatory setbacks could quickly challenge today’s valuation story.

Next Steps

If this Zymeworks story sounds promising, use the momentum as a cue to review the numbers yourself and stress test the upside case. To see why some investors are focused on the potential rewards, take a closer look at the 2 key rewards

Looking for more Zymeworks style investment ideas?

If Zymeworks has sharpened your interest, do not stop here. Use the Simply Wall St screener to explore opportunities that align with your own risk and return preferences.

• Explore potential upside in established businesses by scanning the 51 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect their profiles.
• Prioritise resilience by focusing on companies with strong finances using the list of solid balance sheet and fundamentals (51 results) to keep capital preservation prominent in your process.
• Build a steadier income stream by reviewing the 11 dividend fortresses that pair higher yields with businesses aiming to support ongoing shareholder payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.